VIA
UTHR icon

Vantage Investment Advisors’s United Therapeutics UTHR Stock Holding History

Vantage Investment Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-210
Closed -$25K – 852
2016
Q3 		$25K Hold
210
– – 0.01% 356
2016
Q2 		$22K Hold
210
– – 0.01% 407
2016
Q1 		$23K Hold
210
– – 0.01% 384
2015
Q4 		$33K Hold
210
– – 0.02% 298
2015
Q3 		$28K Hold
210
– – 0.02% 311
2015
Q2 		$37K Buy
+210
New +$37.8K 0.02% 276

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Vantage Investment Advisors's UTHR Position: Q4 2016 in Review

Vantage Investment Advisors sold out of United Therapeutics (UTHR) in Q4 2016, closing a stake of 210 shares — an estimated $25K sold.

Vantage Investment Advisors first reported a position in UTHR in Q2 2015 and held it in 6 quarters. The position peaked at $37K in Q2 2015. 406 funds tracked by Wall St. Rank hold UTHR as of Q4 2016.

  • Vantage Investment Advisors reported no remaining United Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Vantage Investment Advisors sold 210 United Therapeutics shares in Q4 2016, an estimated $25K.
  • Vantage Investment Advisors first reported a position in United Therapeutics in Q2 2015 and held it in 6 quarters.
  • Vantage Investment Advisors's United Therapeutics position peaked at $37K in Q2 2015.
  • 406 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2016.

Based on Vantage Investment Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.